Literature DB >> 10797262

Loss of heterozygosity at chromosome segments 8p22 and 8p11.2-21.1 in transitional-cell carcinoma of the urinary bladder.

C Choi1, M H Kim, S W Juhng, B R Oh.   

Abstract

To identify the putative tumor-suppressor gene (TSG) involved in transitional-cell carcinoma (TCC) of the urinary bladder, we undertook an allelotyping analysis in 48 cases of TCC. Relatively high percentages of allelic loss were found in 2p (5 of 23, 21.7%), 8p (9 of 21, 42.9%), 9p (4 of 20, 20.0%), 12q (6 of 28, 21.4%), 15q (1 of 5, 20%; 4 of 20, 20%), 17p (7 of 26, 26.9%) and 22q (6 of 23, 26.1%). On the basis of these results, fine-deletion mapping was performed on chromosome 8 in 52 cases by PCR of 15 microsatellite markers. Two distinct regions of common deletion were found. A 10 cM telomeric region was located to 8p22, defined by D8S511 and D8S258. A 17 cM centromeric region was located to 8p11.2-21.1, flanked by D8S298 and D8S535. The distance between the telomeric and the centromeric regions of common deletion was 3 cM. Loss of heterozygosity of 8p22 was frequently observed in tumors of high grade or advanced stage. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 10797262     DOI: 10.1002/(sici)1097-0215(20000515)86:4<501::aid-ijc9>3.0.co;2-#

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder.

Authors:  Christine L Chaffer; Bonnie Dopheide; Daniel R McCulloch; Allan B Lee; Jane M Moseley; Erik W Thompson; Elizabeth D Williams
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 2.  What we could do now: molecular pathology of bladder cancer.

Authors:  M A Knowles
Journal:  Mol Pathol       Date:  2001-08

3.  FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells.

Authors:  Andrea Vecchione; Hideshi Ishii; Gustavo Baldassarre; Pierfrancesco Bassi; Francesco Trapasso; Hansjuerg Alder; Francesco Pagano; Leonard G Gomella; Carlo M Croce; Raffaele Baffa
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

Review 4.  Molecular pathogenesis of bladder cancer.

Authors:  Margaret A Knowles
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

5.  Analysis of DLC-1 expression in human breast cancer.

Authors:  Marlies Plaumann; Susanne Seitz; Renate Frege; Lope Estevez-Schwarz; Siegfried Scherneck
Journal:  J Cancer Res Clin Oncol       Date:  2003-05-21       Impact factor: 4.553

6.  Expression of NRG1 and its receptors in human bladder cancer.

Authors:  J A Forster; A B Paul; P Harnden; M A Knowles
Journal:  Br J Cancer       Date:  2011-03-01       Impact factor: 7.640

7.  Down-regulation of Lsm1 is involved in human prostate cancer progression.

Authors:  S Takahashi; S Suzuki; S Inaguma; Y-M Cho; Y Ikeda; N Hayashi; T Inoue; Y Sugimura; N Nishiyama; T Fujita; T Ushijima; T Shirai
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

Review 8.  The Role of Chromosomal Instability in Cancer and Therapeutic Responses.

Authors:  Natalia Vargas-Rondón; Victoria E Villegas; Milena Rondón-Lagos
Journal:  Cancers (Basel)       Date:  2017-12-28       Impact factor: 6.639

9.  Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study.

Authors:  Anja Rogler; Sabine Hoja; Johannes Giedl; Arif B Ekici; Sven Wach; Helge Taubert; Peter J Goebell; Bernd Wullich; Michael Stöckle; Jan Lehmann; Sabrina Petsch; Arndt Hartmann; Robert Stoehr
Journal:  BMC Cancer       Date:  2014-03-20       Impact factor: 4.430

10.  High resolution chromosome 3p, 8p, 9q and 22q allelotyping analysis in the pathogenesis of gallbladder carcinoma.

Authors:  I I Wistuba; A Maitra; R Carrasco; M Tang; P Troncoso; J D Minna; A F Gazdar
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.